Refining basal insulin therapy: what have we learned in the age of analogues?
about
Safety, efficacy, and early clinical experience of insulin degludec in Japanese people with diabetes mellitus: A first-year report from JapanModern basal insulin analogs: An incomplete storyPatient safety and minimizing risk with insulin administration - role of insulin degludecInsulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics.Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.Detemir as a once-daily basal insulin in type 2 diabetesInsulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes.Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patientsCombining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease.Comparison of a multiple daily insulin injection regimen (glargine or detemir once daily plus prandial insulin aspart) and continuous subcutaneous insulin infusion (aspart) in short-term intensive insulin therapy for poorly controlled type 2 diabeteComparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.Evolution of insulin development: focus on key parameters.Insulin degludec: overview of a novel ultra long-acting basal insulin.Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.Basal insulin analogues in the management of diabetes mellitus: What progress have we made?Will the next generation of basal insulins offer clinical advantages?The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomesBioavailability of insulin detemir and human insulin at the level of peripheral interstitial fluid in humans, assessed by open-flow microperfusion.Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.Response to Swinnen et al.Comparison of glycemic variability in Japanese patients with type 1 diabetes receiving insulin degludec versus insulin detemir using continuous glucose monitoring: a randomized, cross-over, pilot study.Insulin therapy for type 2 diabetes
P2860
Q26778763-D4E569C5-267B-4018-A585-69C51B8024FCQ27015047-BA6D2F2E-8CB8-49FE-BEFF-19C930859A2CQ27025548-D2DF288C-9185-4C3D-ACE6-31FD3AEEB76BQ33603473-4C8ECE4C-BB88-4387-BAC4-E3775339F7AFQ33902616-FD874CCE-C082-4435-9449-4783ADC8284BQ34620581-ED50E685-21DC-4C46-937C-1A820DC1A8A1Q35549468-F8785D20-2ABE-421F-BE6E-E21F9862445CQ35683978-E13BEAAD-D85C-44EF-84DD-1466982B0344Q36334638-4EEEE734-1CF6-432B-994E-79BEF2AFB273Q36360080-4D42EF81-2E6E-4A69-971A-CF673C54DF2AQ36426912-DC6C461D-0CC9-4A9A-BE3F-8DFECEE88AD2Q36637960-27EA432C-6A5A-4705-9623-C6B78FFFD22DQ36835841-E6C4BD16-DE23-4E8B-AD69-B3F1A3F3BE13Q36869489-7EE01800-0BA6-4A45-919F-AF34089D1CF7Q37022851-A136347F-D7F6-4A43-AD29-5D8E7978F72AQ37421683-D6431BF1-1B29-4BCB-BC0B-910BB6E62E61Q37594353-37B2B4EB-C7E7-4251-8FDD-794386F25792Q37689556-934AA033-EE9C-45A7-B08D-752B1B16BB53Q38030454-2BDFF962-5C7C-4441-85F6-4C4EDA0B53A8Q38067424-78CD54A4-DD66-429D-9D2B-FA93CFB07088Q38073204-F434D9FC-8D52-4822-9011-C00D99F6B7BBQ38085657-E6D3C0ED-67C3-4E00-B440-6CAE72CBF640Q38136581-39E03DFE-2E63-44F9-9F6C-3752A16EBC1CQ38151948-F4EE4801-5AA9-4A02-B8A0-04CC33E53A5CQ38199712-B0E1C92B-9302-4D88-937F-0DDDB436B3E0Q38824504-96705841-D51E-45E8-AC72-B50BC0465BFAQ40639994-DAC2698B-6C6A-46A6-94F8-977FF8D63E09Q42240405-3B9D5B1F-84C2-4406-9EE6-3F54EFFC054FQ42474726-B022D862-A62C-490B-AAF2-7E2F8713FF29Q51272007-84BCA18E-3755-4433-977A-5AD540A832B2Q58886197-47EF4BD6-0DAC-4AA1-9C6C-C5C09C75A268
P2860
Refining basal insulin therapy: what have we learned in the age of analogues?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Refining basal insulin therapy: what have we learned in the age of analogues?
@en
type
label
Refining basal insulin therapy: what have we learned in the age of analogues?
@en
prefLabel
Refining basal insulin therapy: what have we learned in the age of analogues?
@en
P2860
P356
P1476
Refining basal insulin therapy: what have we learned in the age of analogues?
@en
P2093
P2860
P304
P356
10.1002/DMRR.762
P577
2007-09-01T00:00:00Z